NRIX — Nurix Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-07-24.
Performance
Technicals
Others in Healthcare
Measured signals that fired on NRIX
| date | signal | measured base rate |
|---|---|---|
| 2026-08-11 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-08-05 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-08-05 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-30 | Cluster sale: three or more insiders insider | -0.37% over 21 days · t = -3.38 · n = 21,542 statistically distinguishable from its control group |
| 2026-07-13 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-06-25 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-05 | Hansen Gwenn Chief Scientific Officer | Open-market sale 10b5-1 plan | 4.4K | 25.00 | 108.9K |
| 2026-08-05 | Hansen Gwenn Chief Scientific Officer | Option exercise 10b5-1 plan | 4.4K | 1.86 | 8.1K |
| 2026-08-04 | van Houte Hans Chief Financial Officer | Open-market sale 10b5-1 plan | 3.0K | 24.65 | 73.1K |
| 2026-08-04 | Hansen Gwenn Chief Scientific Officer | Open-market sale 10b5-1 plan | 2.6K | 24.64 | 64.3K |
| 2026-08-04 | van Houte Hans Chief Financial Officer | Open-market sale 10b5-1 plan | 1.8K | 23.89 | 42.9K |
| 2026-08-04 | Hansen Gwenn Chief Scientific Officer | Open-market sale 10b5-1 plan | 1.5K | 23.87 | 35.8K |
| 2026-08-03 | Ring Christine Chief Legal Officer | Open-market sale 10b5-1 plan | 16.6K | 23.05 | 382.4K |
| 2026-08-03 | Ring Christine Chief Legal Officer | Option exercise 10b5-1 plan | 5.8K | 8.72 | 50.5K |
| 2026-07-30 | Hansen Gwenn Chief Scientific Officer | Open-market sale | 3.8K | 23.38 | 90.0K |
| 2026-07-30 | Ring Christine Chief Legal Officer | Open-market sale | 3.8K | 23.38 | 90.0K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 138.3M | 8.9M |
| Redmile Group, LLC | 119.9M | 7.7M |
| Vestal Point Capital, LP | 100.8M | 6.5M |
| Deep Track Capital, LP | 98.4M | 6.3M |
| FMR LLC | 85.9M | 5.5M |
| STATE STREET CORP | 79.7M | 5.1M |
| MORGAN STANLEY | 76.4M | 4.9M |
| BAKER BROS. ADVISORS LP | 72.2M | 4.7M |
| VANGUARD CAPITAL MANAGEMENT LLC | 68.6M | 4.4M |
| GENERAL ATLANTIC, L.P. | 63.6M | 4.1M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about NRIX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →